SEHK:9969Biotechs
What InnoCare Pharma (SEHK:9969)'s New B7-H3 ADC Trial and Pediatric Data Reveal for Shareholders
InnoCare Pharma recently announced two important milestones: the first patient was dosed in a Chinese clinical trial for its novel B7-H3 targeted ADC (ICP-B794), and encouraging new phase I/II clinical data on zurletrectinib for pediatric and adolescent solid tumors was shared at an international oncology congress.
Of particular note, ICP-B794 addresses a significant unmet need as there are currently no B7-H3 targeted therapies approved for marketing globally, highlighting InnoCare’s focus...